Iridex appoints Beverly Huss to board, expanding from five to six members

IRIDEX CORP

Appointment effective March 17, 2022; board size increased from 5 to 6.
Ms. Huss received a nonstatutory stock option for 15,000 shares vesting monthly over 4 years.
She brings over 25 years of medical device management and board experience.
Currently CEO of Pagonia Medical; former CEO of Qool Therapeutics and Guidant executive.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Beverly A. Huss

Director

IRIX · IRIDEX CORP

Effective: 2022-03-17
Filed: March 21, 2022, 7:59 PM ET

On March 17, 2022, Iridex Corporation (the “ Company ”) appointed Beverly A. Huss to its board of directors (the “ Board ”), effective March 17, 2022 (the “ Effective Date ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Beverly A. Huss was appointed as Director at IRIDEX CORP.

Action: appointed
Role: Director

Exact text from the filing

On March 17, 2022, Iridex Corporation (the “ Company ”) appointed Beverly A. Huss to its board of directors (the “ Board ”), effective March 17, 2022 (the “ Effective Date ”).

View on SEC.gov

IRIDEX CORP filing history →

Source: SEC EDGAR

accession 0001564590-22-011195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.